Immunotherapy, including anti-PD-1/PD-L1 and CTLA-4 has been more and more widely used in HNSCC (Pitt et al., 2016; Dogan et al., 2018; Fasano et al., 2022). Here, CTLA4 is linked to head and neck squamous cell carcinoma.